Skip to main content

Natural killer cell-mediated anti-viral and anti-tumour defence and therapy: Integrated research training in molecular medicine, bioinformatics and issues of patent application and the SME biotech business

Objective

The development of novel technologies of immuno-therapies holds great promise for potential future treatment of hitherto difficult to cure viral diseases and tumours. It is to be anticipated that such technologies will provide the physician with potent novel therapies and will be the basis for the establishment and growth of new biotech SMEs. This proposal suggests therefore to combine research work on natural killer (NK) cell immune defences and therapies, with training in bio-informatics and issues of patent applications and management of the biotech business.

The research part will deal with mechanisms of the innate immune defence used to control viral infections and tumours. It will focus on receptors used by NK and some myeloid cells to interact with surf ace structures exposed by virally infected and/or tumour cells. Firstly, it will investigate the mechanisms developed by viruses and tumours to avoid or subvert immune defences. In this respect viruses have evolved a large number of genes, which function to interfere with the expression of ligands that could be used by NK cells to trace infected cells. Similarly, many of the same or related target molecules can be found down regulated in tumour cells. Secondly, we will use the molecules recognized by receptors on NK and myeloid cells to develop technologies to boost immune reactions.

This will be done by:
i) by specific reagents directing immune cells to the infected/malignant target cells and
ii) by genetically engineering NK cells to provide them with increased activities.

We intend to train the students of this RTN in all techniques of immuno-technology including wider aspects of molecular medicine by enrolling them in the established MD/PhD programs of the respective Universities. An exchange of students between the different partners will be organized to ensure that every participant will be trained at different places. Training in bio-informatics using the NK and leukocyte receptor complexes of the human genome.

Call for proposal

FP6-2004-MOBILITY-1
See other projects for this call

Funding Scheme

RTN - Marie Curie actions-Research Training Networks

Coordinator

MEDICAL UNIVERSITY OF VIENNA
Address
Spitalgasse 23
Vienna
Austria

Participants (11)

AFFIMED THERAPEUTICS AG
Germany
Address
Technologiepark, Im Neuenheimer Feld 582
Heidelberg
ANTHONY NOLAN TRUST / NOTTINGHAM TRENT UNIVERSITY
United Kingdom
Address
Royal Free Hospital, Pond Street, Hampstead
London
CHANCELLORS MASTERS & SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
Address
The Old Schools, Trinity Lane
Cambridge
COPENHAGEN BUSINESS SCHOOL
Denmark
Address
Solberg Plads 3
Frederiksberg
EUROPEAN MOLECULAR BIOLOGY LABORATORY
United Kingdom
Address
Meyerhofstrasse 1
Heidelberg
EUROPEAN PATENT ORGANISATION
Germany
Address
Erhardtstr. 27
Munich
HEINRICH HEINE UNIVERSITY DÜSSELDORF
Germany
Address
Moorenstrasse 5
Düsseldorf
THE HEBREW UNIVERSITY OF JERUSALEM
Israel
Address
The Authority For Research And Developement, Edmond J. Safra Campus Givat Ram
Jerusalem
UNIVERSITAT POMPEU FABRA
Spain
Address
Plaça De La Mercè, 10-12
Barcelona
UNIVERSITY OF RIJEKA MEDICAL SCHOOL
Croatia
Address
Brace Branchetta 20
Rijeka
VIENNA UNIVERSITY OF ECONOMICS AND BUSINESS ADMINISTRATION
Austria
Address
Augasse 2-6
Vienna